Candel Therapeutics, Inc. (CADL)
NASDAQ: CADL · Real-Time Price · USD
10.18
+0.02 (0.20%)
At close: Oct 2, 2026, 4:00 PM EDT
10.20
+0.02 (0.20%)
After-hours: Oct 2, 2026, 7:51 PM EDT
Candel Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
55
Market Cap
778.96M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 125.00K | - | - |
| Dec 31, 2021 | 125.00K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Geron | 204.56M |
| Gyre Therapeutics | 109.82M |
| 4D Molecular Therapeutics | 92.01M |
| Wave Life Sciences | 65.37M |
| Lexicon Pharmaceuticals | 41.47M |
| Attovia Therapeutics | 1.80M |
| Avalo Therapeutics | 59.00K |
CADL News
- 2 days ago - Candel Therapeutics to Present at the SITC 2026 Annual Meeting - GlobeNewsWire
- 3 days ago - Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 3 days ago - Candel announces final phase 2a trial of aglatimagene, valacyclovir - TheFly
- 3 days ago - Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI - GlobeNewsWire
- 4 days ago - Candel Therapeutics announces data from phase 2 PrTK05 trial - TheFly
- 4 days ago - Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer - GlobeNewsWire
- 4 days ago - Candel Therapeutics announces new data on aglatimagene besadenovec - TheFly
- 4 days ago - Candel Therapeutics Announces New Data Showing Sustained Immune Remodeling More Than Two Years After Aglatimagene Besadenovec Treatment in Localized Prostate Cancer at ASTRO 2026 - GlobeNewsWire